"目录号: HY-13859
Clevudine能抗乙肝病毒。
相关产品
Tenofovir Disoproxil Fumarate-Squalamine-Merimepodib-Entecavir monohydrate-Adefovir dipivoxil-Bay 41-4109-Bicyclol-Telbivudine-Osalmid-Helioxanthin 8-1-Helioxanthin derivative 5-4-2-Lagociclovir-Oxethazaine-
生物活性
Description
Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].
Clinical Trial
Bukwang Pharmaceutical
Chronic Hepatitis B
November 2007
Phase 4
Triangle Pharmaceuticals
Hepatitis B
August 2002
Phase 2
French National Agency for Research on AIDS and Viral Hepatitis-Gilead Sciences-Pharmasset
HBe Negative Chronic Hepatitis B-Hepatitis B Viral Infection
December 2008
Phase 3
Bukwang Pharmaceutical
Chronic Hepatitis B
June 2007
Phase 4
Bukwang Pharmaceutical
Chronic Hepatitis B
November 2009
Phase 4
Bukwang Pharmaceutical
Hepatitis B
July 2003
Phase 2
Bukwang Pharmaceutical
Patients With LC-B
December 2007
Phase 3
Bukwang Pharmaceutical
Hepatitis B
July 2002
Phase 2
Bukwang Pharmaceutical
Hepatitis B
June 2003
Phase 3
Bukwang Pharmaceutical
Hepatitis B
July 2003
Phase 3
Bukwang Pharmaceutical
Hepatitis B
June 2004
Phase 3
Bukwang Pharmaceutical
Chronic Hepatitis B
March 2010
Phase 4
Bukwang Pharmaceutical
Chronic Hepatitis B
September 2009
Phase 4
Bukwang Pharmaceutical
HBeAg(+) Chronic Hepatitis B
December 2008
Phase 4
Bukwang Pharmaceutical
Hepatitis B Associated Hepatocellular Carcinoma
June 2010
Phase 4
Bukwang Pharmaceutical
Hepatitis B
August 2006
Phase 3
Bukwang Pharmaceutical
Hepatitis B
June 2003
Phase 2
Bukwang Pharmaceutical
Hepatitis B
May 2007
Phase 4
Bukwang Pharmaceutical
Chronic Hepatitis B
August 2009
Phase 4
Bukwang Pharmaceutical
HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
February 2008
Phase 4
Inje University-Bukwang Pharmaceutical
Chronic Hepatitis B
December 2008
Phase 4
Eisai Co., Ltd.-Eisai Inc.
Chronic Hepatitis B
February 2010
Phase 3
Pharmasset
Chronic Hepatitis-Hepatitis B
August 2007
Phase 3
Pharmasset
Chronic Hepatitis-Hepatitis B
August 2007
Phase 3
Bukwang Pharmaceutical
Healthy
April 2012
Phase 1
University of Southern California-National Cancer Institute (NCI)
HER2-positive Breast Cancer-Recurrent Breast Cancer-Stage IA Breast Cancer-Stage IB Breast Cancer-Stage II Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer
November 22, 2013
View MoreCollapse
References
